Skip to main content
Top
Published in: International Cancer Conference Journal 4/2017

01-10-2017 | Case report

A case of ovarian growing teratoma syndrome treated by cytoreductive surgery

Authors: Yuko Goto, Akiyoshi Mizumoto, Masamitsu Hirano, Nobuyuki Takao, Masumi Ichinose, Kousuke Noguchi, Ippei Kasyu, Mitsuaki Ishida, Yutaka Yonemura

Published in: International Cancer Conference Journal | Issue 4/2017

Login to get access

Abstract

Ovarian growing teratoma syndrome (GTS) is a rare disease characterized by growth of a benign tumor during or after chemotherapy, following the removal of germ cell gonadal cancers. Although benign, GTS tumors grow gradually and may compress surrounding organs. In addition, up to 3% of GTS cases can undergo malignant transformation. It is, therefore, needed to treat GTS. No standardized management protocol has been established to treat GTS; however, surgical resection is likely the only effective treatment because tumors in GTS are resistant to chemotherapy and radiation therapy. However, complete resection with conventional procedures is sometimes difficult when peritoneal metastasis is widespread. We report a rare case of ovarian GTS with widespread peritoneal metastases, which was totally resected by peritonectomy procedures. A 45-year-old Japanese woman was initially diagnosed with an immature teratoma grade 3, which was treated by hysterectomy and bilateral salpingo-oophorectomy. Adjuvant chemotherapy was performed after surgery with bleomycin, etoposide, cisplatin, and other chemotherapies. Due to recurrence of a chemoresistant tumor and normalization of tumor markers, GTS was suspected. She was referred to our institute, and complete cytoreductive surgery was performed using peritonectomy procedures, including parietal peritoneal resection, greater omentectomy, lesser omentectomy, rectosigmoid colectomy, diaphragm dissection, and cholecystectomy. A complete cytoreduction with no visible residual tumor tissue was achieved.
Literature
2.
go back to reference André F, Fizazi K, Culine S et al (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer Oxf Engl 1990 36:1389–1394 André F, Fizazi K, Culine S et al (2000) The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer Oxf Engl 1990 36:1389–1394
4.
go back to reference DiSaia PJ, Saltz A, Kagan AR, Morrow CP (1977) Chemotherapeutic retroconversion of immature teratoma of the ovary. Obstet Gynecol 49:346–350PubMed DiSaia PJ, Saltz A, Kagan AR, Morrow CP (1977) Chemotherapeutic retroconversion of immature teratoma of the ovary. Obstet Gynecol 49:346–350PubMed
6.
go back to reference Hong WK, Wittes RE, Hajdu ST et al (1977) The evolution of mature teratoma from malignant testicular tumors. Cancer 40:2987–2992CrossRefPubMed Hong WK, Wittes RE, Hajdu ST et al (1977) The evolution of mature teratoma from malignant testicular tumors. Cancer 40:2987–2992CrossRefPubMed
9.
go back to reference Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–907. doi:10.1097/SLA.0b013e3181a45d86 CrossRefPubMed Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 249:900–907. doi:10.​1097/​SLA.​0b013e3181a45d86​ CrossRefPubMed
10.
go back to reference Mizumoto A, Canbay E, Hirano M et al (2012) Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. doi:10.1155/2012/836425 Mizumoto A, Canbay E, Hirano M et al (2012) Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. doi:10.​1155/​2012/​836425
13.
go back to reference Yuen PM, Yu KM, Yip SK et al (1997) A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 177:109–114CrossRefPubMed Yuen PM, Yu KM, Yip SK et al (1997) A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 177:109–114CrossRefPubMed
14.
go back to reference Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society of Reproductive Surgeons (2013) Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery: a committee opinion. Fertil Steril 99:1550–1555. doi:10.1016/j.fertnstert.2013.02.031 CrossRef Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society of Reproductive Surgeons (2013) Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery: a committee opinion. Fertil Steril 99:1550–1555. doi:10.​1016/​j.​fertnstert.​2013.​02.​031 CrossRef
16.
Metadata
Title
A case of ovarian growing teratoma syndrome treated by cytoreductive surgery
Authors
Yuko Goto
Akiyoshi Mizumoto
Masamitsu Hirano
Nobuyuki Takao
Masumi Ichinose
Kousuke Noguchi
Ippei Kasyu
Mitsuaki Ishida
Yutaka Yonemura
Publication date
01-10-2017
Publisher
Springer Japan
Published in
International Cancer Conference Journal / Issue 4/2017
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-017-0304-z

Other articles of this Issue 4/2017

International Cancer Conference Journal 4/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine